Year in Review in Axial Spondyloarthritis Clinical Research and Guidelines: SPARTAN 2023 Annual Meeting Proceedings.
Curr Rheumatol Rep
; 26(5): 164-169, 2024 05.
Article
en En
| MEDLINE
| ID: mdl-38340269
ABSTRACT
PURPOSE OF REVIEW To highlight high impact clinical publications in spondyloarthritis from May 2022 to April 2023 that were summarized and presented at the SPARTAN annual meeting in May 2023. RECENT FINDINGS:
Publications included updated guidelines on management of axial spondyloarthritis (axSpA) by ASAS-EULAR and development of a modified Juvenile Spondyloarthritis Disease Activity Index (JSpADA). Definitions were published for MRI lesions of the spine in axSpA and active and structural sacroiliac (SI) joint lesions in juvenile spondyloarthritis (JSpA). Anatomic variants of the sacroiliac joint were commonly detected using synthetic CT derived from pelvis MRI images. Anti-CD74 antibodies hold promise as a diagnostic biomarker for axSpA; however, the mechanism of such antibody development seems unrelated to gastrointestinal inflammation. High impact clinical publications in spondyloarthritis addressed lab-based and imaging biomarkers, outcome measures, and updated management guidelines.Palabras clave
Texto completo:
1
Bases de datos:
MEDLINE
Asunto principal:
Espondiloartritis Axial
Tipo de estudio:
Guideline
Límite:
Humans
Idioma:
En
Revista:
Curr Rheumatol Rep
/
Curr. rheumatol. rep
/
Current rheumatology reports
Asunto de la revista:
REUMATOLOGIA
Año:
2024
Tipo del documento:
Article
País de afiliación:
Estados Unidos